指南与共识慢性肾脏病肾血管病与高血压

KDIGO慢性肾脏病-矿物质与骨异常争议会议结论

Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
指南 / 共识 · Kidney Int · 2025-01-24

与会者认为2017指南推荐仍基本一致,但三部分框架或不再最佳,建议未来指南以CKD相关骨质疏松和CKD相关心血管病两种临床综合征组织,并强调个体化管理。

要点

  • 2017 CKD-MBD指南推荐仍基本与现有证据一致
  • 未来指南可考虑以CKD相关骨质疏松和CKD相关心血管病为框架
  • CKD-MBD骨与心血管表现复杂,需个体化管理

核心结论

  • 2017 CKD-MBD指南推荐仍基本与现有证据一致,但框架可能需要调整。
  • 未来指南可考虑以CKD相关骨质疏松和CKD相关心血管病两种临床综合征组织。

主要发现

  • 新证据涉及矿物质代谢与骨质量/骨转换评估、血管钙化识别与抑制、维生素D水平靶向及甲状旁腺激素调节。
  • 与会者强调CKD-MBD骨与心血管表现复杂,需要个体化管理。

关键数值与推荐

  • 2017指南包含三个主要部分:矿物质代谢生化异常、骨病和血管钙化。
  • 未来指南可考虑CKD相关骨质疏松(涵盖骨折风险增加)和CKD相关心血管病(包括血管钙化及瓣膜钙化、左心室肥厚等结构异常)。

临床怎么用

  • 临床可继续遵循2017 CKD-MBD指南推荐。
  • 管理应注重个体化,综合考虑骨与心血管表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care. Participants concluded that the recommendations in the 2017 CKD-MBD guideline remained largely consistent with the available evidence. However, the framework of the 2017 Guideline, with 3 major sections-biochemical abnormalities in mineral metabolism; bone disease; and vascular calcification-may no longer best reflect currently available evidence related to diagnosis and treatment. Instead, future guideline efforts could consider mineral homeostasis and deranged endocrine systems in adults within a context of 2 clinical syndromes: CKD-associated osteoporosis, encompassing increased fracture risk in patients with CKD; and CKD-associated cardiovascular disease, including vascular calcification and structural abnormalities, such as valvular calcification and left ventricular hypertrophy. Participants emphasized that the complexity of bone and cardiovascular manifestations of CKD-MBD necessitates personalized approaches to management.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Ketteler M, Evenepoel P, Holden RM, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025. PMID: 39864017. doi:10.1016/j.kint.2024.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。